BNP Paribas Financial Markets
DMIIR

BNP Paribas Financial Markets’s Drugs Made In America Acquisition II Corp Right DMIIR Stock Holding History

BNP Paribas Financial Markets’s Portfolio DMIIR Stock Details DMIIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.9K Hold
348,600
– – ﹤0.01% 4973
2025
Q4 		$48.8K Buy
+348,600
New +$49.8K ﹤0.01% 4696

Other funds holding DMIIR

MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return

BNP Paribas Financial Markets's DMIIR Position: Q1 2026 in Review

BNP Paribas Financial Markets held its Drugs Made In America Acquisition II Corp Right (DMIIR) position steady in Q1 2026 at 348,600 shares worth $27.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4973.

BNP Paribas Financial Markets first reported a position in DMIIR in Q4 2025 and has held it in 2 quarters since. The position peaked at $48.8K in Q4 2025. 57 funds tracked by Wall St. Rank hold DMIIR as of Q1 2026.

  • BNP Paribas Financial Markets held 348,600 shares of Drugs Made In America Acquisition II Corp Right worth $27.9K as of Q1 2026.
  • BNP Paribas Financial Markets left its Drugs Made In America Acquisition II Corp Right share count unchanged in Q1 2026.
  • Drugs Made In America Acquisition II Corp Right made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #4973 holding.
  • BNP Paribas Financial Markets first reported a position in Drugs Made In America Acquisition II Corp Right in Q4 2025 and has held it in 2 quarters since.
  • BNP Paribas Financial Markets's Drugs Made In America Acquisition II Corp Right position peaked at $48.8K in Q4 2025.
  • 57 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp Right as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.